Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival

Checkpoint inhibitors have revolutionized the treatment of patients with metastasized melanoma. However, it remains unclear when to stop treatment. We retrospectively analyzed 45 patients (median age 64 years; 58% male) with metastasized melanoma from 3 cancer centers that received checkpoint inhibi...

Full description

Bibliographic Details
Main Authors: Timo E. Schank, Andrea Forschner, Michael Max Sachse, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Albrecht Stenzinger, Anna-Lena Volckmar, Alexander Enk, Jessica C. Hassel
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
FDG-PET-CT scan
melanoma
outcome
checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/13/11/2616

Internet

https://www.mdpi.com/2072-6694/13/11/2616

Similar Items